RecruitingPhase 3NCT07213674
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Sponsor: Amgen
Arlington, TX · Dallas, TX · Houston, TX · +43 more sites